Yanagihara T - Search Results

1

Therapeutic targets and early stage clinical trials for pulmonary fibrosis.

Sato S, Yanagihara T, Kolb MRJ. Sato S, et al. Among authors: yanagihara t. Expert Opin Investig Drugs. 2019 Jan;28(1):19-28. doi: 10.1080/13543784.2019.1554054. Epub 2018 Dec 6. Expert Opin Investig Drugs. 2019. PMID: 30513000 Review.

2

Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in lung fibrosis.

Bellaye PS, Shimbori C, Yanagihara T, Carlson DA, Hughes P, Upagupta C, Sato S, Wheildon N, Haystead T, Ask K, Kolb M. Bellaye PS, et al. Among authors: yanagihara t. Eur Respir J. 2018 Jan 31;51(2):1700386. doi: 10.1183/13993003.00386-2017. Print 2018 Feb. Eur Respir J. 2018. PMID: 29386344 Free article.

3

Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension.

Bellaye PS, Yanagihara T, Granton E, Sato S, Shimbori C, Upagupta C, Imani J, Hambly N, Ask K, Gauldie J, Iglarz M, Kolb M. Bellaye PS, et al. Among authors: yanagihara t. Eur Respir J. 2018 Aug 30;52(2):1701857. doi: 10.1183/13993003.01857-2017. Print 2018 Aug. Eur Respir J. 2018. PMID: 29976656 Free article.

4

Molecular breath analysis for IPF: Can we make a few breaths count?

Yanagihara T, Kolb M. Yanagihara T, et al. Respirology. 2019 May;24(5):404-405. doi: 10.1111/resp.13503. Epub 2019 Feb 12. Respirology. 2019. PMID: 30747465 Free article. No abstract available.

5

Mechanical stress-induced mast cell degranulation activates TGF-β1 signalling pathway in pulmonary fibrosis.

Shimbori C, Upagupta C, Bellaye PS, Ayaub EA, Sato S, Yanagihara T, Zhou Q, Ognjanovic A, Ask K, Gauldie J, Forsythe P, Kolb MRJ. Shimbori C, et al. Among authors: yanagihara t. Thorax. 2019 May;74(5):455-465. doi: 10.1136/thoraxjnl-2018-211516. Epub 2019 Feb 26. Thorax. 2019. PMID: 30808717

6

What have we learned from basic science studies on idiopathic pulmonary fibrosis?

Yanagihara T, Sato S, Upagupta C, Kolb M. Yanagihara T, et al. Eur Respir Rev. 2019 Sep 11;28(153):190029. doi: 10.1183/16000617.0029-2019. Print 2019 Sep 30. Eur Respir Rev. 2019. PMID: 31511255 Free PMC article. Review.

7

Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.

Wongkarnjana A, Yanagihara T, Kolb MR. Wongkarnjana A, et al. Among authors: yanagihara t. Expert Rev Respir Med. 2019 Dec;13(12):1139-1146. doi: 10.1080/17476348.2019.1673733. Epub 2019 Oct 9. Expert Rev Respir Med. 2019. PMID: 31564185 Review.

8

Current models of pulmonary fibrosis for future drug discovery efforts.

Yanagihara T, Chong SG, Vierhout M, Hirota JA, Ask K, Kolb M. Yanagihara T, et al. Expert Opin Drug Discov. 2020 Aug;15(8):931-941. doi: 10.1080/17460441.2020.1755252. Epub 2020 May 12. Expert Opin Drug Discov. 2020. PMID: 32396021 Review.

9

Fibrotic extracellular matrix induces release of extracellular vesicles with pro-fibrotic miRNA from fibrocytes.

Sato S, Chong SG, Upagupta C, Yanagihara T, Saito T, Shimbori C, Bellaye PS, Nishioka Y, Kolb MR. Sato S, et al. Among authors: yanagihara t. Thorax. 2021 Sep;76(9):895-906. doi: 10.1136/thoraxjnl-2020-215962. Epub 2021 Apr 15. Thorax. 2021. PMID: 33859055

10

Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications.

Yanagihara T, Scallan C, Ask K, Kolb MRJ. Yanagihara T, et al. Expert Opin Ther Targets. 2021 Nov;25(11):939-948. doi: 10.1080/14728222.2021.2006186. Epub 2021 Dec 16. Expert Opin Ther Targets. 2021. PMID: 34784834 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

586 results

Search Page

Filters